Sign in
MBIO Stock Price, Chart, Stats & News
Mustang Bio, Inc.
Save
5.11M
Market cap
–
Current P/E
–
Forward P/E
MBIO chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -10.92% |
ROE | -29.78% |
D/E | – |
Interest coverage ratio | – |
MBIO valuation
P/E | – |
P/S | – |
P/B | 0.55x |
P/CF | -1.00x |
P/FCF | -1.04x |
P/OCF | -1.00x |
PEG | -0.04x |
EV multiple | -10.65x |
About
Mustang Bio, Inc. is a clinical-stage biopharmaceutical firm dedicated to transforming groundbreaking advancements in cell and gene therapies into potential therapeutic options for hematological malignancies, solid tumors, and uncommon genetic conditions. Its research and development efforts are primarily directed towards gene therapy programs for rare genetic disorders and chimeric antigen receptor (CAR) T-cell treatments for both blood cancers and various solid tumors. Among its lead gene therapy candidates are MB-107 and MB-207, designed to address X-linked severe combined immunodeficiency.
Similar securities
Based on sector and market capitalization
Report issue